ProQR Therapeutics N.V. Stock Analysis & AI Score
ProQR Therapeutics N.V. (PRQR) has an ST Score of 41.1 (C), driven by its Forecast (B+) and held back by its Financial Strength (D). Analysts rate it Buy with a $3.00 price target (+75.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
ProQR Therapeutics N.V. (PRQR) has an ST Score of 41.1 (C), driven by its Forecast (B+) and held back by its Financial Strength (D). Analysts rate it Buy with a $3.00 price target (+75.4% upside).
- Strongest
- ForecastB+
- Weakest
- Financial StrengthD
All factor grades
- ForecastB+
- ValuationB-
- MomentumB-
- ProfitabilityC+
- GrowthC-
- Financial StrengthD
- Piotroski1/9
Contact
PRQR stock: frequently asked questions
What is PRQR's ST Score?
ProQR Therapeutics N.V. (PRQR) has an ST Score of 41.1 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PRQR a buy, hold, or sell?
Analysts rate PRQR a Buy, with a price target of $3.00 (+75.4% vs the current price). Our ST Score grades it C (41.1/100). The ST Score is a data-driven signal, not a recommendation.
What are PRQR's factor grades?
Valuation B-, Profitability C+, Financial Strength D, Momentum B-, Growth C-, Forecast B+.
What is PRQR's valuation grade?
ProQR Therapeutics N.V. (PRQR) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PRQR's growth grade?
ProQR Therapeutics N.V. (PRQR) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PRQR's profitability grade?
ProQR Therapeutics N.V. (PRQR) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PRQR's financial strength grade?
ProQR Therapeutics N.V. (PRQR) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PRQR?
The average analyst price target for ProQR Therapeutics N.V. (PRQR) is $3.00 from 12 analysts, which is +75.4% versus the recent price of $1.71.
What is PRQR's Piotroski score?
ProQR Therapeutics N.V. (PRQR) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.